What the FDA thinks about Arimistane?

The FDA attacked arimistane (also known as “Androsta-3,5-Diene-7,17-Dione”, “3-deoxy-7-oxo-DHEA”, or sometimes “3,7-keto DHEA”) by claiming that VMI Sports was perpetuating false claims about the health benefits of the ingredient. They even classified arimistane as a “new drug”.They cited section “201(p) of the […]

Tagged ,
Read More

OSTARINE (MK-2866) – Enobosarm – GTx-024 – S-22

GTx acknowledged today that its sole clinical-phase drug candidate enobosarm has failed a Phase II trial in women with stress urinary incontinence—a failure that sent shares free-falling more than 90% back in september—but stopped short of saying whether it will halt the […]

Tagged ,
Read More